{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-155612","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2024-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.578050+00:00","generated_at":"2026-06-01T05:48:48.953031+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaccinex completes last patient visit in SIGNAL-AD Phase 1b/2 Alzheimer's study","bullets":["Last patient completed final visit in randomized, double-blind Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease.","Database lock expected in June; key outcomes including safety, FDG-PET, and plasma GFAP biomarkers to be reported in July.","Pepinemab targets SEMA4D to inhibit astrocyte reactivity and neuroinflammation, a differentiated mechanism vs. anti-amyloid antibodies.","Study funded by $4.75M from ADDF and $0.75M grant from Alzheimer's Association."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-155612","json":"https://secwatch.observer/filing/0001193125-24-155612.json","markdown":"https://secwatch.observer/filing/0001193125-24-155612.md","text":"https://secwatch.observer/filing/0001193125-24-155612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524155612/0001193125-24-155612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312524155612/d756458d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:48:48.953031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}